Lars Lannfelt

Principal Investigator
Alzheimers Disease / Geriatrics

Professor in Geriatrics, Uppsala University, Member of the Royal Swedish Academy of Science (KVA), more than 200 scientific papers of which some have become citation classics, most important are the papers on the Swedish Alzheimer mutation (Nature Genetics 1992) and the Arctic Alzheimer mutation (Nature Neuroscience 2001). Founder of BioArctic Neuroscience AB with Pär Gellerfors (CEO). The idea for treatment of Alzheimer’s disease is based on mechanisms revealed by the Arctic mutation. Phase I clinical trials are starting the summer of 2010.

My field of expertise is molecular mechanisms of Alzheimer’s disease and other neurodegenerative disorders as well as biomarkers and future treatments of these disorders.

The Berzelii centre provides us with a broad local network in Uppsala located at different faculties and with a wide range of expertice.

My goal is to have developed treatments for Alzheimer’s and Parkinson’s disease that are able to stop the progression of disease.


Uppsala Berzelii Technology Centre for Neurodiagnostics | Email